Medicover Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Fredrik Rågmark

Chief Executive Officer (CEO)

€2.6m

Compensación total

Porcentaje del salario del CEO	39.0%
Permanencia del CEO	27.3yrs
Participación del CEO	1.0%
Permanencia media de la dirección	3.8yrs
Promedio de permanencia en la Junta Directiva	14.8yrs

Actualizaciones recientes de la dirección

Recent updates

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Apr 22

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

Apr 04

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Mar 05

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Feb 11

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Jun 12

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

May 27

Is Medicover (STO:MCOV B) Using Too Much Debt?

May 12

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Feb 16

Is Medicover (STO:MCOV B) Using Too Much Debt?

Jan 30

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Dec 30

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Dec 17

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Oct 30

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Oct 16

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Sep 09

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Jul 25

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Jul 12

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Jun 13

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?

May 29

With EPS Growth And More, Medicover (STO:MCOV B) Is Interesting

Apr 20

Medicover (STO:MCOV B) Could Easily Take On More Debt

Apr 08

Medicover (STO:MCOV B) Is Doing The Right Things To Multiply Its Share Price

Mar 15

Is Now The Time To Look At Buying Medicover AB (publ) (STO:MCOV B)?

Feb 25

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Fredrik Rågmark en comparación con los beneficios de Medicover?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	€22m
Dec 31 2023	n/a	n/a	€18m
Sep 30 2023	n/a	n/a	€8m
Jun 30 2023	n/a	n/a	€6m
Mar 31 2023	n/a	n/a	€2m
Dec 31 2022	€3m	€1m	€12m
Sep 30 2022	n/a	n/a	€37m
Jun 30 2022	n/a	n/a	€59m
Mar 31 2022	n/a	n/a	€88m
Dec 31 2021	€2m	€952k	€102m
Sep 30 2021	n/a	n/a	€93m
Jun 30 2021	n/a	n/a	€90m
Mar 31 2021	n/a	n/a	€52m
Dec 31 2020	€2m	€670k	€26m
Sep 30 2020	n/a	n/a	€14m
Jun 30 2020	n/a	n/a	€4m
Mar 31 2020	n/a	n/a	€16m
Dec 31 2019	€1m	€900k	€23m
Sep 30 2019	n/a	n/a	€19m
Jun 30 2019	n/a	n/a	€19m
Mar 31 2019	n/a	n/a	€20m
Dec 31 2018	€1m	€807k	€22m
Sep 30 2018	n/a	n/a	€28m
Jun 30 2018	n/a	n/a	€26m
Mar 31 2018	n/a	n/a	€23m
Dec 31 2017	€921k	€810k	€19m

Compensación vs. Mercado: La compensación total de Fredrik($USD2.78M) está por encima de la media de empresas de tamaño similar en el mercado Swedish ($USD791.05K).

Compensación vs. Ingresos: La compensación de Fredrik ha sido consistente con los resultados de la empresa en el último año.

CEO

Fredrik Rågmark (60 yo)

27.3yrs

Permanencia

€2,602,000

Compensación

Mr. Fredrik Ragmark serves as the Chief Executive Officer of Medicover AB (publ). Mr. Ragmark has been employed with Medicover since 1996. He serves as Managing Director and Board Member of Kalvskär AB.Fr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Rågmark	CEO & Director	no data	€2.60m	1.05% € 283.7m
Joe Ryan	Chief Financial Officer	no data	sin datos	0.92% € 249.3m
Jaroslaw Urbanczyk	Chief Information Officer	4.6yrs	sin datos	0.0040% € 1.1m
Hanna Bjellquist	Head of Investor Relations	no data	sin datos	sin datos
Jenny Brandt	General Legal Counsel	no data	sin datos	0.035% € 9.5m
Andrew Vallance-Owen	Chief Marketing Officer	no data	sin datos	sin datos
Kamila Skorupinski	Group Chief People Officer	less than a year	sin datos	sin datos
John Stubbington	Chief Operating Officer of Healthcare Services	8.3yrs	sin datos	0.49% € 131.8m
Staffan Ternstrom	Chief Operating Officer for Diagnostic Services	2.9yrs	sin datos	0.033% € 9.1m

3.8yrs

Permanencia media

58yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de MCOV B se considera experimentado (3.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Fredrik Rågmark	CEO & Director	27.3yrs	€2.60m	1.05% € 283.7m
Robert Jochnick	Independent Director	17.3yrs	€54.60k	1.22% € 330.1m
Fredrik Stenmo	Independent Chairman	19.3yrs	€101.50k	4.42% € 1.2b
Margareta Nordenvall	Independent Director	23.3yrs	€66.20k	0.060% € 16.3m
Arno Bohn	Independent Director	23.3yrs	€63.05k	0.20% € 54.4m
Cecil Michael Flemming	Independent Director	9.3yrs	€78.30k	sin datos
Anne Berner	Independent Director	2.1yrs	€59.85k	sin datos
Azita Shariati	Independent Director	2.1yrs	€63.05k	0.0015% € 399.1k
Peder Jochnick	Independent Director	12.3yrs	€54.60k	2.6% € 704.7m
Sonali Chandmal	Independent Director	7.3yrs	€71.45k	0.017% € 4.5m

14.8yrs

Permanencia media

59.5yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de MCOV B son experimentados ( 14.8 años antigüedad media).

Medicover Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Independent Chairman recently bought kr3.9m worth of stock

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Recent updates

Medicover AB (Publ) Provides Revenue Guidance for Year-End 2025

First quarter 2024 earnings released: EPS: €0.041 (vs €0.01 in 1Q 2023)

Upcoming dividend of €0.12 per share

Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects

Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings

New minor risk - Earnings quality

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Dividend of €0.12 announced

Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price

Full year 2023 earnings: EPS exceeds analyst expectations

Now 24% undervalued

Medicover AB (publ) Provides Earnings Guidance for the Financial Year 2025

Medicover Appoints Kamila Skorupinski as Chief People Officer as of 1 April 2024

Consensus EPS estimates increase by 27%

Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Independent Chairman recently bought kr3.9m worth of stock

New minor risk - Earnings quality

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Provides Revenue Targets for by Year-End 2025

Medicover AB (Publ) Announces Resignation of Joe Ryan as Chief Financial Officer

Independent Director recently bought kr303k worth of stock

Medicover AB (publ) Announces Nomination Committee for the Annual General Meeting 2024

Medicover AB (publ), Annual General Meeting, Apr 26, 2024

Medicover's (STO:MCOV B) Returns On Capital Not Reflecting Well On The Business

Medicover (STO:MCOV B) Has A Somewhat Strained Balance Sheet

Independent Director recently bought kr1.4m worth of stock

Independent Chairman recently bought kr6.3m worth of stock

Second quarter 2023 earnings released: EPS: €0.037 (vs €0.01 in 2Q 2022)

Medicover AB (publ) to Report Q1, 2024 Results on Apr 26, 2024

Insider recently bought kr242k worth of stock

Is There An Opportunity With Medicover AB (publ)'s (STO:MCOV B) 37% Undervaluation?

Chief Information Officer recently bought kr321k worth of stock

Medicover (STO:MCOV B) Will Want To Turn Around Its Return Trends

Is Medicover (STO:MCOV B) Using Too Much Debt?

Consensus EPS estimates fall by 10%

Now 21% undervalued after recent price drop

Upcoming dividend of €0.12 per share at 0.7% yield

Full year 2022 earnings: Revenues in line with analyst expectations

Consensus EPS estimates fall by 72%

Now 23% undervalued

Full year 2022 earnings: Revenues in line with analyst expectations

Medicover AB (publ) Proposes Dividend for 2022

Returns On Capital At Medicover (STO:MCOV B) Have Hit The Brakes

Consensus EPS estimates fall by 26%

Is Medicover (STO:MCOV B) Using Too Much Debt?

Investor sentiment improved over the past week

Is Medicover AB (publ) (STO:MCOV B) Potentially Undervalued?

Estimating The Fair Value Of Medicover AB (publ) (STO:MCOV B)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Medicover AB (publ) to Report Q2, 2023 Results on Jul 26, 2023

Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger

Medicover AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023

Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?

Medicover AB (publ) (OM:MCOV B) acquired Übag Mvz Meindentist Gbr.

Medicover AB (publ) (OM:MCOV B) completed the acquisition of Laurus Medical SRL.

Medicover AB (publ), Annual General Meeting, Apr 27, 2023

Should You Think About Buying Medicover AB (publ) (STO:MCOV B) Now?

Estimating The Intrinsic Value Of Medicover AB (publ) (STO:MCOV B)

Second quarter 2022 earnings: Revenues exceed analyst expectations

Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet

Independent Chairman recently bought kr2.8m worth of stock

Medicover AB (publ) (OM:MCOV B) acquired Konzilijum.

Investors Met With Slowing Returns on Capital At Medicover (STO:MCOV B)

Medicover AB (publ) (OM:MCOV B) signed an agreement to acquire Übag Mvz Meindentist Gbr.

High number of new directors

At kr179, Is It Time To Put Medicover AB (publ) (STO:MCOV B) On Your Watch List?